Today, a Director at Tandem Diabetes (TNDM), Howard Greene, sold shares of TNDM for $430.6K.
Following Howard Greene’s last TNDM Sell transaction on February 13, 2018, the stock climbed by 34.4%. In addition to Howard Greene, 3 other TNDM executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Tandem Diabetes’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $46.26 million and GAAP net loss of $34.25 million. In comparison, last year the company earned revenue of $27 million and had a GAAP net loss of $16.04 million. Currently, Tandem Diabetes has an average volume of 1.94M. The Company has a Price to Book ratio of 18.2883.
Based on 7 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $51.14, reflecting a 29.3% upside.
In the last 30 days, insiders have sold $8.34M worth of TNDM shares and purchased $49.08K worth of TNDM shares.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
